Latest news with #rituximab
Globe and Mail
6 days ago
- Health
- Globe and Mail
Dermatomyositis Market Set to Advance with Improved Diagnosis and Emerging Immunotherapies by 2034
Dermatomyositis is a rare, chronic, inflammatory myopathy characterized by progressive muscle weakness and distinctive skin rashes, often associated with autoimmune mechanisms. It can occur in both adults and children and may involve complications such as interstitial lung disease, malignancy, and calcinosis. Despite its rarity, dermatomyositis remains a significant clinical concern due to its multisystem involvement, diagnostic complexity, and limited treatment options. DelveInsight's ' Dermatomyositis Market Insight, Epidemiology, and Market Forecast – 2034 ' provides an in-depth analysis of the current landscape and future outlook of the DM market across major geographies, including the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The report explores detailed epidemiological trends, segmentation by age and clinical subtypes, and diagnostic challenges that contribute to underreporting and delayed intervention. Current treatment regimens typically include corticosteroids, immunosuppressants (methotrexate, azathioprine), intravenous immunoglobulin (IVIG), and emerging biologics like rituximab. However, response rates vary, and long-term use can lead to significant side effects. A growing pipeline of investigational agents—targeting pathways such as type I interferons and B-cell modulation—offers promising avenues for disease-specific and steroid-sparing therapies. The Dermatomyositis market is projected to witness steady growth through 2034, fueled by increased disease recognition, clinical trial activity, and strategic advancements by pharmaceutical companies. Biotech firms and academic institutions are exploring novel immunomodulatory agents and precision medicine approaches to improve outcomes in both adult and pediatric populations. DelveInsight's report is an essential resource for pharmaceutical executives, clinical researchers, investors, and healthcare professionals who seek strategic insights into the evolving DM landscape, from market dynamics and unmet needs to the competitive pipeline shaping the future of dermatomyositis care. Some of the Key Facts of the Dermatomyositis Market Report: • In 2023, the dermatomyositis market in the 7MM was valued at approximately USD 187 million, and is projected to grow at a CAGR of 16.8% due to improved disease awareness, diagnostics, and the introduction of new therapies. • The U.S. had the highest number of diagnosed cases, with around 38.5K in 2023. • Across the 7MM, there were nearly 72K diagnosed prevalent cases in 2023, with 91% in adults and 9% in juveniles. • The U.S. accounted for ~54% of total diagnosed cases, while EU4 and the UK represented about 29%, and Japan ~17%. • In January 2025, RESTEM announced that the FDA granted Fast Track designation for its Restem-L program, using umbilical cord outer lining stem cells (ULSCs) to treat Polymyositis and Dermatomyositis (PM/DM), now classified as Idiopathic Inflammatory Myopathy (IIM). This follows the recent Orphan Drug Designation for Restem-L in IIM. • In July 2024, Priovant Therapeutics announced the completion of enrollment for its Phase 3 VALOR trial evaluating brepocitinib in dermatomyositis. With 241 participants across 90 sites on four continents, it is the largest interventional trial ever conducted for the condition. • Leading companies in the Dermatomyositis market include Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals, and others. • Emerging acute Dermatomyositis drugs include KZR-616, EFG PH20, PF 06823859, Hizentra, Daxdilimab, PN 101, Ravulizumab, and others. • The increasing prevalence of dermatomyositis and ongoing advancements in therapeutic options are driving the demand for more effective treatment approaches. To know in detail about the dermatomyositis market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Dermatomyositis Market Forecast Dermatomyositis Overview Dermatomyositis is a rare, systemic autoimmune disorder characterized by chronic inflammation of the skin and muscles. It presents with hallmark features such as symmetric proximal muscle weakness and distinctive skin rashes, including the heliotrope rash and Gottron's papules. The condition may also affect other organs, including the lungs, esophagus, and heart, and is sometimes associated with malignancy, especially in adults. Dermatomyositis affects both adults and children (juvenile dermatomyositis), with varying severity. Its exact etiology remains unclear but is believed to involve a combination of genetic predisposition, immune system dysregulation, and environmental triggers. Diagnosis typically involves a combination of clinical findings, elevated muscle enzymes, electromyography (EMG), imaging studies, skin/muscle biopsies, and autoantibody testing. Management of dermatomyositis requires a multidisciplinary approach, involving dermatologists, rheumatologists, neurologists, and physical therapists. While there is no cure, a range of therapies aim to control inflammation, alleviate symptoms, and prevent complications. Get a free sample of the dermatomyositis market report with key insights and emerging therapies here: Dermatomyositis Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Dermatomyositis Epidemiology Segmentation: The Dermatomyositis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by: • Diagnosed Dermatomyositis prevalence • Type-specific Diagnosed Dermatomyositis prevalence • Age-specific Diagnosed Dermatomyositis prevalence • Gender-specific Diagnosed Prevalent Cases of Dermatomyositis • Severity-specific Diagnosed Prevalent Cases of Dermatomyositis • Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis Download the report to understand which factors are driving dermatomyositis epidemiology trends @ Dermatomyositis Epidemiology Forecast Dermatomyositis Drugs Uptake and Pipeline Development Activities The Dermatomyositis drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the Dermatomyositis market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug. Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share. The report further delves into the Dermatomyositis pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies. Dermatomyositis Market Outlook While there is no definitive cure for dermatomyositis, available treatments aim to reduce inflammation, control symptoms, and improve quality of life. The approval of OCTAGAM and the development of multiple clinical management guidelines—such as those from the British Society for Rheumatology and the Japanese Society of Rheumatology—have significantly shaped and standardized the therapeutic landscape. Treatment often begins with corticosteroids to manage muscle inflammation, followed by immunosuppressants or immunomodulators like methotrexate, azathioprine, or mycophenolate mofetil to reduce steroid dependency. For resistant or severe cases, advanced therapies such as rituximab, IVIG, and calcineurin inhibitors are employed. In terms of skin manifestations, management includes both topical agents (e.g., corticosteroids, calcineurin inhibitors) and systemic medications like hydroxychloroquine. Adjunctive strategies such as physiotherapy, sun protection, and dietary interventions are also integral. A growing pipeline featuring therapies like Brepocitinib (Priovant/Pfizer), Dazukibart (Pfizer), Efgartigimod (Argenx), and SAPHNELO (AstraZeneca) reflects an evolving research focus on immunomodulation and interferon signaling pathways. These emerging agents, combined with better diagnostics and increasing disease awareness, are expected to drive market growth through 2034. Dermatomyositis Market Strengths • A strong research focus on immune pathways (e.g., JAK-STAT, interferon) has led to promising investigational drugs such as Brepocitinib and Anifrolumab, indicating future therapeutic breakthroughs. • Increasing awareness among clinicians and availability of diagnostic tools (e.g., autoantibody profiling, MRI) enable earlier diagnosis and more tailored treatment strategies. Dermatomyositis Market Weaknesses • Despite multiple treatment options, none offer a cure, and many patients experience relapses or partial responses, necessitating lifelong management. • A significant portion of treatment regimens relies on off-label drug use, which lacks robust clinical trial data, leading to variable efficacy and safety outcomes across patient populations. Scope of the Dermatomyositis Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] • Key Dermatomyositis Companies: Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals, and others. • Key Dermatomyositis Therapies: KZR-616, EFG PH20, PF 06823859, Hizentra, Daxdilimab, PN 101, Ravulizumab, and others. • Dermatomyositis Therapeutic Assessment: Dermatomyositis, currently marketed, and Dermatomyositis emerging therapies • Dermatomyositis Market Dynamics: Dermatomyositis market drivers and Dermatomyositis market barriers • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies • Dermatomyositis Unmet Needs, KOL's views, Analyst's views, Dermatomyositis Market Access and Reimbursement To learn more about the key players and advancements in the dermatomyositis treatment landscape, visit the Dermatomyositis Market Analysis Report Table of Contents 1. Dermatomyositis Market Report Introduction 2. Executive Summary for Dermatomyositis 3. SWOT analysis of Dermatomyositis 4. Dermatomyositis Patient Share (%) Overview at a Glance 5. Dermatomyositis Market Overview at a Glance 6. Dermatomyositis Disease Background and Overview 7. Dermatomyositis Epidemiology and Patient Population 8. Country-Specific Patient Population of Dermatomyositis 9. Dermatomyositis Current Treatment and Medical Practices 10. Dermatomyositis Unmet Needs 11. Dermatomyositis Emerging Therapies 12. Dermatomyositis Market Outlook 13. Country-Wise Dermatomyositis Market Analysis (2020–2034) 14. Dermatomyositis Market Access and Reimbursement of Therapies 15. Dermatomyositis Market Drivers 16. Dermatomyositis Market Barriers 17. Dermatomyositis Appendix 18. Dermatomyositis Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Medscape
12-05-2025
- Health
- Medscape
Rituximab Shows Long-Term Benefits in Follicular Lymphoma
Early rituximab monotherapy led to a substantial delay in the need for new treatment in patients with advanced stage, asymptomatic, low tumour burden follicular lymphoma. After a median follow-up duration of 14.7 years, researchers found no detrimental effect on the time to initiation of second new treatment or overall survival. METHODOLOGY: Researchers conducted an open-label, randomised, phase 3 trial in which 455 patients with asymptomatic, stage II-IV, grade 1-3a low tumour burden follicular lymphoma were randomly assigned in a 1:1:1 ratio to the watchful waiting (n = 183), rituximab induction (n = 82), or rituximab maintenance (n = 190) group. Rituximab induction comprised 375 mg/m 2 intravenous doses weekly for 4 weeks, and the rituximab maintenance group received additional 12 doses every 8 weeks at the same dose. intravenous doses weekly for 4 weeks, and the rituximab maintenance group received additional 12 doses every 8 weeks at the same dose. The primary endpoint was the time to initiation of new treatment (TTNT), defined as the time from randomisation until the first day of systemic chemotherapy or radiotherapy initiation. This study reported long-term results of the trial over a median follow-up duration of 14.7 years. TAKEAWAY: At 15 years, 65% (95% CI, 56-72) of patients in the rituximab maintenance group, 48% (95% CI, 36-60) of patients in the rituximab induction group, and 34% (95% CI, 27-42) of patients in the watchful waiting group had not started new treatment. The median TTNT was 5.6 years (95% CI, 3.8-8.4) in the watchful waiting group, 14.8 years (95% CI, 7.5 to not reached) in the rituximab induction group, and not reached (95% CI, 15.6 to not estimable) in the rituximab maintenance group. The TTNT was significantly longer for patients in both rituximab groups than for those in the watchful waiting group (rituximab induction vs watchful waiting: hazard ratio [HR], 0.55; 95% CI, 0.38-0.80; P = .0019; rituximab maintenance vs watchful waiting: HR, 0.36; 95% CI, 0.26-0.50; P < .0001). = .0019; rituximab maintenance vs watchful waiting: HR, 0.36; 95% CI, 0.26-0.50; < .0001). No significant differences in overall survival were observed between the groups at 15 years (rituximab maintenance, 73%; rituximab induction, 66%; and watchful waiting, 68%). Similarly, no significant differences in the risk for high-grade transformation and the time to initiation of second new treatment were observed between the groups. IN PRACTICE: "Early rituximab monotherapy could therefore be considered a standard treatment option for patients with advanced stage, asymptomatic low tumour burden follicular lymphoma and the optimal approach should be considered on an individual patient basis," the authors concluded. SOURCE: This study was led by Michael Northend, University College London Hospitals NHS Foundation Trust, London, England. It was published online in The Lancet Haematology . LIMITATIONS: This study was limited by the lack of long-term toxicity data, especially for patients receiving rituximab maintenance, and the early closure of the rituximab induction group, which limited the power of any comparisons with the four-dose rituximab induction regimen. DISCLOSURES: This study received funding from Cancer Research UK, the Lymphoma Research Trust, Lymphoma Action, and Roche. Roche provided rituximab free of charge. Additional disclosures are noted in the original article. Several authors reported receiving honoraria and consultancy fees and having other ties with various sources.
Medscape
12-05-2025
- Health
- Medscape
Prophylaxis in Vasculitis Cuts Risk for Non-PJP Infections
Prophylactic treatment with trimethoprim-sulfamethoxazole (TMP-SMX) significantly reduced the risk for serious infections by approximately 50% in patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis, with the greatest benefits observed during the first 180 days of treatment. METHODOLOGY: Researchers conducted an observational study that used a target trial emulation framework to examine the effect of prophylactic TMP-SMX on the incidence of serious infections in patients with ANCA-associated vasculitis. They included 296 patients with new-onset or relapsing ANCA-associated vasculitis from four tertiary referral hospitals in South Korea who received either rituximab or cyclophosphamide as induction therapy between 2005 and 2023. Of these, 240 patients received TMP-SMX prophylaxis (prophylaxis group; mean age, 63.7 years; 55.8% women) within 14 days of induction therapy, and 56 patients did not receive prophylaxis (control group; mean age, 61.5 years; 60.7% women) during the same period. Physicians at each institution determined patient eligibility for prophylactic TMP-SMX, with dosage being either one single-strength tablet (TMP 80 mg and SMX 400 mg) daily or one double-strength tablet (TMP 160 mg and SMX 800 mg) every other day, adjusted for renal function. The primary outcome was the incidence of serious infections requiring intravenous antimicrobial treatment, hospitalization, or extended hospital stay. Secondary outcomes included infection-related deaths and severe adverse drug reactions related to TMP-SMX. TAKEAWAY: Approximately 45.8% of patients discontinued the use of prophylactic TMP-SMX within the first 180 days. During 252.1 person-years of observation, 77 serious infections occurred in 65 patients, with an incidence rate of 30.5 per 100 person-years and a fatality rate of 18.5%. Most serious infections (85.7%) occurred within the first 180 days of observation (incidence rate ratio, 5.43; 95% CI, 2.87-10.28). The prophylaxis group had a significantly lower 1-year incidence than the control group (hazard ratio [HR], 0.48; 95% CI, 0.32-0.72), particularly during the first 180 days (HR, 0.41; 95% CI, 0.22-0.76) but not thereafter (HR, 3.76; 95% CI, 0.46-29.43). Infection-related mortality was also significantly lower in the prophylaxis group than in the control group (HR, 0.23; 95% CI, 0.10-0.53). Over 127.4 person-years of TMP-SMX prophylaxis, 35 cases of adverse events occurred, eight of which were adverse drug reactions related to prophylactic TMP-SMX, and 27 patients discontinued TMP-SMX. Only one case of severe adverse drug reaction was noted, which was resolved after treatment discontinuation. IN PRACTICE: 'Our results strongly suggest that prophylactic TMP-SMX provides additional benefits in patients with AAV [ANCA-associated vasculitis] beyond reducing the risk of PJP [ Pneumocystis jirovecii pneumonia],' the authors wrote. SOURCE: This study was led by Yun Kyu Kim, MD, Seoul National University College of Medicine, Seoul, Republic of Korea, and was published online on April 14, 2025, in Arthritis & Rheumatology . LIMITATIONS: Unmeasured confounders, such as compliance with prophylactic TMP-SMX, may have influenced the findings. The varied duration of TMP-SMX use in the prophylaxis group, with many patients discontinuing within 180 days, may have led to biased estimates. Additionally, the impact of TMP-SMX on COVID-19 incidence and related infectious complications could not be estimated for patients with an index date prior to 2018. DISCLOSURES: This study was supported by a grant from the National Research Foundation of Korea. One author reported receiving salary from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Two authors reported receiving grants and consulting fees from various pharmaceutical companies.
Medscape
08-05-2025
- Health
- Medscape
Rituximab's Role in Lupus Set for Further Randomized Trials
MANCHESTER, England — Two new randomized controlled trials (RCTs) assessing the role of rituximab in the treatment of various stages of systemic lupus erythematosus (SLE) have the green light to start, experts involved in their planning announced at the British Society for Rheumatology (BSR) 2025 Annual Meeting. The STRATIFY Lupus study will recruit people with established SLE to investigate whether it is possible to personalize treatment with rituximab followed by belimumab based on baseline serum immunoglobulin A2 (IgA2) anti–double-stranded DNA (dsDNA) antibody concentrations. Meanwhile, the First-Line Rituximab in Systemic Lupus Trial (FIRST) will study the use of rituximab in people newly diagnosed with SLE. 'We're in quite an exciting position in lupus in the UK at the moment because we have not one, but two national-scale RCTs that are about to start,' said Edward Vital, PhD, a professor in autoimmune connective tissue diseases and an honorary consultant rheumatologist at the University of Leeds, Leeds, England; the chair of the BSR's Special Interest Group for SLE; and the chair of the British Isles Lupus Assessment Group (BILAG). 'These trials are very difficult to get funding for, and they are even more difficult to execute. So, it is something we are all going to have to focus on together, especially those of us who are sites or are referring patients to sites,' added Vital, the co-lead investigator for FIRST. STRATIFY Lupus Michael Ehrenstein, PhD, professor in rheumatology at University College London (UCL) and consultant rheumatologist for UCL Hospital, London, England, agreed that conducting clinical trials in lupus was 'incredibly challenging from a recruitment point of view.' Michael Ehrenstein, PhD Ehrenstein is the co-lead investigator for the STRATIFY Lupus trial alongside Muhammad Shipa, MRCP, also of UCL, who has noted that the trial would be the first ever biomarker-enriched trial for patients with SLE. STRATIFY Lupus comes 10 years after funding for the phase 2 BEAT-LUPUS trial was obtained. The results of that trial were published in 2021 and showed that giving the anti–B-cell activating factor drug belimumab after the B-cell–depleting therapy rituximab was 'safe,' said Ehrenstein, and the combination significantly reduced the risk for severe flares of disease vs rituximab alone in people who had refractory SLE. A subsequent exploratory analysis published 2 years later found that baseline serum IgA2 anti-dsDNA was predictive of a major clinical response to the use of belimumab after rituximab. The difference in achieving a major clinical response at 1 year with the combination was 48% vs 35% for rituximab alone, a difference of just 13%. But when these data were stratified according to whether serum IgA2 anti-dsDNA levels had been high or low at baseline, the major clinical response rates were 64.3% with the combination vs 16.7% for rituximab alone, a difference of 48%. 'The delta jumps from 13% to 48%,' Ehrenstein said. 'Wouldn't it be great to have trials in lupus where you have a delta of 48% between the two arms? That would cause incredible excitement.' Trial Setup and Design STRATIFY Lupus will officially be set up in June, with a target accrual of 66 patients with established SLE and high levels of IgA2 anti-dsDNA antibodies. Recruitment is expected to take 2 years, with the first patients enrolled in February or March next year. The current plan is that after an initial 4- to 8-week screening period, during which all patients will receive treatment with rituximab, patients will be randomly allocated to receive belimumab as well as rituximab or to continue with rituximab alone. 'The idea is that, if you treated patients with belimumab after rituximab, those with high levels of IgA2 anti-dsDNA antibody would be much more likely to respond compared [with] if you just treated with rituximab, which is the standard of care at the moment,' Ehrenstein said. Similar to BEAT-LUPUS, the primary endpoint will be major clinical response at 1 year. This is personalized medicine, he added. The results of the trial could potentially help guide clinicians and their patients to decide on the best course of treatment. If IgA2 anti-dsDNA levels are low, 'you just continue with what you were going to do anyway, which is give them rituximab. If they're high, you give them a belimumab, and then you follow it with rituximab.' Safety and Protocol Challenges One of the concerns of using belimumab and rituximab together has been safety, and specifically the possibility of a higher rate of serious infections than rituximab alone. In fact, the prescribing information for belimumab states that the two should not be used in combination. However, looking at data from the phase 3 randomized, controlled BLISS-BELIEVE trial in context with other trials such as BEAT-LUPUS and CALIBRATE in lupus nephritis, Ehrenstein said, 'We were able to persuade [belimumab manufacturer] GSK [GlaxoSmithKline] that we thought that giving belimumab may well make rituximab safer and certainly wouldn't cause any issue.' Notably, he added, with the study population enriched to be potentially more likely to obtain a clinical response, the benefit-to-risk ratio should be tipped more in favor of the combination than rituximab alone. There could be some protocol and recruitment challenges, Ehrenstein said, such as whether rituximab would still be the go-to for the standard of care, with evidence mounting for the role of mycophenolate mofetil in refractory lupus and a potentially increased uptake of the B-cell–depleting drug obinutuzumab (Gazyva). And, because only 30%-50% of patients with refractory SLE may have high IgA2 anti-dsDNA levels, considerably more patients would need to be screened than was the case for BEAT-LUPUS. Competition from other teams conducting clinical trials in lupus was also a consideration for obtaining sufficient accrual. Trialing First-Line Rituximab Switching to discuss the FIRST trial, Md Yuzaiful Md Yusof, PhD, consultant rheumatologist and senior research fellow at the University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, England, noted that a grant of £2.6 million has been secured from the National Institute for Health and Care Research (NIHR) to fund the trial. Md Yuzaiful Md Yusof, PhD Although 'there is a long way ahead,' hopefully when the trial reports in 2029, it will show whether there is a benefit to using rituximab earlier in the course of the disease, Md Yusof said. The rationale is that in the first year of diagnosis, compared with later time points, patients with SLE have 'the worst disease activity' and 'tend to use a lot of glucocorticoids' and tend to have high healthcare costs, he said. 'Also, as we all know that, if we treat our patients late, this also may affect long-term outcomes, including organ damage, health, quality of life, etc.,' he added. FIRST will be a multicenter, double-blind, superiority trial that will aim to recruit 128 patients within 12 months of a diagnosis of moderate to severe SLE across 20 sites in the United Kingdom. Patients will receive standard care treatment, including oral immunosuppressants, and be randomly allocated to treatment with either rituximab or placebo. Primary Endpoint The primary endpoint of FIRST will be cumulative time spent in Lupus Low Disease Activity State (LLDAS) at 12 months rather than response using the SLE Disease Activity Index 2000. LLDAS is the cumulative time where SLE disease activity is adequately controlled on an acceptable dose of glucocorticoids, and it is a meaningful clinical endpoint according to people living with the disease, Md Yusof said. Vital, the co-lead investigator for the trial, later said, 'I increasingly think that our concept of response has been a mistake in the world of lupus.' Indeed, the main trials that have been conducted with rituximab in the past, and which largely yielded negative results, used response assessment at set time points as their primary endpoints, but it has long been known that everyone is fluctuating up and down in their response over the course of treatment, Vital observed. His comment was in response to some unpublished data from the BILAG Biologics Register (BILAG BR) that had been presented by Ian Bruce, MD, professor of rheumatology at the University of Manchester, Manchester, England, and pro vice chancellor of Medicine, Health, and Life Sciences at Queen's University Belfast, Belfast, Ireland. These data showed that there appear to be six distinct trajectories of response to rituximab, one of which showed an initial response to treatment but then a flare at about 9 months, which resolved by 12 months. So, 'if you choose your landmark at 6 months, they would all be responders. If you choose your landmark at 12 months, they'll be responders. You might actually miss the flare if you were tracking them that way,' Bruce said. Inclusion criteria for FIRST are a diagnosis of SLE within the past 12 months and aged 5 years or older. Treatment with a first immunosuppressant can occur at screening or not more than 4 weeks prior, so long as patients have a minimum of one BILAG-A grade, two BILAG-B grades, or one BILAG-B grade plus mucocutaneous involvement with physician intent to treat with immunosuppression. So far, 24 groups have come forward to participate in the study, but there is still room for more teams to get involved, Md Yusof said. STRATIFY Lupus is being funded by Versus Arthritis and the NIHR's Efficacy and Mechanism Evaluation (EME) Researcher-led Program, with contributions from Lupus UK and belimumab being provided by GSK. Ehrenstein had received consultancy fees from AbbVie, GSK, and UCB, and grant/research support from GSK. Ehrenstein and Shipa are named on a UCL patent application for the use of IgA2 anti-dsDNA antibodies as a biomarker in SLE. FIRST is being funded by the NIHR. Md Yusof had received consultancy, advisory board, or speaker fees from Alumis, Aurinia, GSK, Novartis, Roche, UCB, and Vifor. Vital is the co-lead investigator for FIRST and sits on the steering committee of the Lupus Forum, which is supported with educational grants and other donations from various companies, including AbbVie, AstraZeneca, Aurinia, Biogen, Bristol Myers Squibb (BMS), GSK, Merck, Novartis, Roche, Otsuka, and UCB. BILAG-BR had received funding support from Roche, GSK, and Lupus UK. Bruce had received research and clinical trial funding from AstraZeneca, GSK, Janssen, and Otsuka. He had also received honoraria, consultation, advisory board, or speaker fees from AstraZeneca, BMS, Eli Lilly & Company, GSK, Novartis, and UCB. Sara Freeman is a medical journalist based in London, England.
